Benzodiazepine receptor stimulation blocks scopolamine-induced learning impairments in a water maze task

• Published in: Brain research bulletin Vol. 41; no. 5; pp. 299 - 304
• Main Authors: SMYTHE, J. W, MURPHY, D, COSTALL, B
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Science 1996
• Subjects: Animals; Anxiety - psychology; Behavioral psychophysiology; Biological and medical sciences; Cognition - drug effects; Diazepam - pharmacology; Fundamental and applied biological sciences. Psychology; GABA Modulators - pharmacology; GABA-A Receptor Agonists; Male; Maze Learning - drug effects; Memory - drug effects; Muscarinic Antagonists - pharmacology; Neurotransmission and behavior; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Rats; Scopolamine - antagonists & inhibitors; Scopolamine - pharmacology; Affect affectivity; Rat; Corticosterone; Memory; Rodentia; ACTH; Benzodiazepine receptor; Learning; Vertebrata; Mammalia; Acquisition process; Adenohypophyseal hormone; Animal; Neurotransmitter; Acetylcholine; Anxiety
• ISSN: 0361-9230; 1873-2747
• DOI: 10.1016/S0361-9230(96)00198-0

Central cholinergic (ACh) blockade produces profound cognitive impairments in human and animal subjects. Our previous research demonstrated that ACh blockade exacerbates stress-induced adrenocorticotrophin (ACTH) and corticosterone (CORT) secretion, and increases anxiety-like behavior (ALB) in rats. The fact that all these responses occur following the same manipulation led us to question whether or not increases in ALB might play a part in the cognitive deficits. This issue was all the more intriguing given that anxiolytic agents such as benzodiazepines are reported to produce learning and memory impairments on their own. We reasoned that a low dose of diazepam (DZP) with no apparent cognitive effects itself, might be able to antagonize an impairment induced by scopolamine (SCOP). Adult male Lister rats (n = 6/group) were administered IP either vehicle (VEH), 0.5 mg/kg DZP, 0.25 mg/kg SCOP, or 0.5 mg/kg DZP, followed 20 min later by 0.25 mg/kg SCOP, and tested 20 min later in a water maze for latency to locate a hidden platform and for path length taken to the platform. Rats were tested in an acquisition phase (Day 1) and a retention phase (Day 2), as well as on a visually guided task. On Day 1, SCOP produced a marked acquisition deficit that was unaffected by DZP. DZP by itself had no obvious effect. However, whereas SCOP resulted in a persistent deficit on the retention task (Day 2), pretreatment with DZP prior to SCOP on Day 1 completely abolished the impairment. There were no group differences on the visually cued task. We contend that SCOP-induced cognitive deficits may, in part, be due to increases in ALB. Stimulation of benzodiazepine receptors may offset the loss of cholinergic systems underlying consolidation mechanisms, but not those mediating immediate task performance. Whether this effect of DZP relates to an action on ALB remains to be elucidated.